Effective from November 22, 2016, ScinoPharm (Changshu) Pharmaceuticals, Ltd. has changed its English name to “ SciAnda (Changshu) Pharmaceuticals. Ltd.”.
ScinoPharm Taiwan, Ltd (TWSE: 1789) and CVie Therapeutics Limited (CVie) jointly announced the initiation of a discovery and development collaboration to identify the new generation compound to Istaroxime,
ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2015.
ScinoPharm (TWSE:1789) today announced that the 6.4-magnitude earthquake struck an area in the island’s southwest at 3:57 a.m. on February 6, 2016 did not cause any personnel injuries nor any structural or facility damage.
ScinoPharm (TWSE:1789) today announced that its subsidiary, ScinoPharm Changshu, located in the Changshu Economic Development Zone in Jiangsu Province, China, has successfully completed a cGMP inspection by the US FDA with no resulting 483 concerns or comments.